Xia Qing M.D., Ph.D.
Professor, Department of Chemical Biology, School of Pharmacy
Research Areas
Biotechnology
Biodefense
Education & Positions
ShandongMedical University of China, Clinical Medicine, 1997.
Shandong Academy of Medical Sciences of China, M.S in Immunology, 2000.
Peking University Health Science Center, M.D & Ph.D. in Pathology, 2004.
Peking University, Postdoctoral Fellow in Inorganic Chemistry, 2004-2006.
Peking University, School of Pharmacy, Assistant Professor 2006-2011, Associate Professor 2011-2017, Professor 2017-.
University of Southern California, Visiting Scholar in School of Pharmacy, 2010-2011.
Harvard Medical School, Visiting Scholar in Boston Children's Hospital, 2014-2015.
Medical Licensure
Shandong Province in China, 1999-.
Faculty Accolades
Beijing Science and Technology Young Scholars Award 2011.
Lvye Outstanding Young Scholar Award in Peking University, 2016.
Key Field Innovation Team of the Ministry of Science and Technology (the 5th position), 2016.
The Second prize in Natural Science of the Ministry of Education (the 9th position), 2013.
Research Interests
Approximately one-third of alleles causing genetic diseases carry premature termination codons (PTCs), which lead to the production of truncated proteins. Our laboratory seeks better therapeutic approaches aimed at readthrough of in-frame PTCs to enable synthesis of full-length proteins, including genetic incorporation of unnatural amino acids, suppressor tRNAs, stem cell therapy, single base editing systems to treat PTC-mediated diseases. We study the mechanistic underpinnings of PTC suppression, including the efficiency of termination differs between normal stop codons and premature termination codons. Meanwhile we established 17 types of PTC stable cell lines containing unnatural amino acids incorporation systems, suppressor tRNAs, or Heavy/light chain antibodiesto develop virus vaccines and therapeutic antibodies for biodefense.
Grants and fundings
● 2017-2020, National Major Scientific and Technological Project for “Significant New Drugs Discovery”,
Novel Strategies for Development of Biodefense Virus Vaccines and Therapeutic Antibodies.
RMB: 20,000,000.
Role: Principal Investigator
● 2017-2020, National Major Scientific and Technological Project for “Significant New Drugs Discovery”,
Pluripotent Stem Cell-derived Brain and Lung Organoid Systems for Antiviral Drug Screening and Disease Modeling.
RMB: 6,000,000.
Role: Principal Investigator
● 2014-2017, National Natural Science Foundation of China,
Biomineralization Molecular Mechanism in the Pineal Gland.
RMB: 800,000
Role: Principal Investigator
●2017-2018, National Natural Science Foundation of China,
Regenerative Potential of Skeletal Muscle Stem Cells Using Expanded Amino Acid Repertoire.
RMB: 300,000
Role: Principal Investigator
Publications
1. Lu J, Cheng K, Zhang B, Xu H, Cao Y, Guo F, Feng X, Xia Q*. Novel mechanisms for superoxide-scavenging activity of human manganese superoxide dismutase determined by the K68 key acetylation site.Free Radic Biol Med. 2015, 85:114-26.
2. Lu J, Zhang H, Chen X, Zou Y, Li J, Wang L, Wu M, Zang J, Yu Y, Zhuang W, Xia Q*,Wang J*. A small molecule activator of SIRT3 promotes deacetylation and activation of manganese superoxide dismutase. Free Radic Biol Med. 2017,112, 287-297.
3. Lu J, Cao Y, Cheng K, Wang T, Yang Q, Feng X, Xia Q*. Berberine regulates neurite outgrowth through AMPK-dependent pathways by lowering energy status.Exp Cell Res. 2015, 334, 194-206.
4. Zhang B, Yang Q, Xu H, Wu Y, Wu L, Yao T, Zhang L, Xia Q*, Zhou D*. CRISPRi-Manipulation of Genetic Code Expansion via RF1 for Reassignment of Amber Codon in Bacteria. Sci Rep. 2016, Jan 28; 6: 20000.
5. Wang W, Zhao Z, Zhang Z, Zhang C, Xiao S, Ye X, Zhang L, Xia Q*, Zhou D*. Redirect Killer T Cells via Displaying Azido Sugar for Tethering Ligands. Chembiochem. 2017, 18, 2082-2086.
